2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009

CBIS African Delegation Arrives in Johannesburg, South Africa After Successful Cape Town Meetings With South African Parliament Members, University Cannabis Research Specialists, and Tour of NIH Equivalent, South African Medical Research Council (MRC)

CBIS African Delegation Arrives in Johannesburg, South Africa After Successful Cape Town Meetings With South African Parliament Members, University Cannabis Research Specialists, and Tour of NIH Equivalent, South African Medical Research Council (MRC)

JOHANNESBURG, SOUTH AFRICA--(Marketwired - May 25, 2016) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines -- The CBIS delegation led by Mr. Raymond C. Dabney has arrived in Johannesburg, South Africa after a series of successful meetings and in-depth discussions in Cape Town, South Africa with South African Parliament members, key University cannabis research specialists, private industry front-runners, topped off with a tour and meetings with key executives at the South African Medical Research Council (MRC) which is the NIH equivalent research organization in South Africa.

Dr. Herman, CBIS's Chief Medical Officer (CMO) spent 5 years during his early career working as a scientist at the South African Medical Research Council (MRC). He was the institution's first scientist of color.

"It was a pleasure to see so many of my former work associates still working at the MRC. I spent my early scientific career with the individuals we met with and who have become leading scientists in South Africa. South Africa is a country with diverse populations; it has individuals with sound clinical and scientific skills; and traditional populations with a long history of cultural and medicinal use of cannabis. Our meetings with the people I have known for many years will most assuredly have a positive impact in our drug development program. They have committed to work with CBIS to find effective approaches to cannabinoid drug development. This obviously gives us great confidence in the success of our endeavors to bring strong research and drug development using cannabis in the region," stated Dr. Herman.

While in Johannesburg, the CBIS delegation will be joined by Dr. Julius Garvey, a member of Scientific Advisory Board (SAB) of CBIS. Dr. Garvey landed in Johannesburg earlier to complete a previous engagement as he was invited to give the Robert Sobukwe lecture today at the Steve Biko Foundation. Robert Sobukwe was the founder of the Pan Africanist Congress (PAC) in South Africa and Steve Biko the founder of the South African Black Consciousness Movement. Steve Biko was a former fellow medical school student colleague of Dr. Herman. Dr. Garvey is the son of Marcus Garvey, one of the pioneers of Pan Africanism and a former US and Jamaican civil rights stalwart.

"Working with community partners, nationally recognized policy experts, researchers, and clinical care specialists in Cape Town is very important to us. We also had deep discussions of the cultural role and use of cannabis among aboriginal South Africans, and the increasing availability and use of medical cannabis in South Africa with cultural advisors to South African community and political leaders. We look forward to advancing our initiatives in short order," stated President & CEO Raymond C. Dabney. 

"We are very pleased to be joined by Dr. Garvey for the remainder of our African journey. We have identified a number of regulatory and political experts who will assist CBIS in having an efficient South African drug development program. After these series of initial meetings our delegation clearly understands the state of medical cannabis research in South Africa, and the increasing interest of researchers to develop needed programs that will improve our insight into medical cannabis treatment options. We have identified the paths to success to introduce these new drugs into South Africa. The legislative leaders and governing bodies have stated their interest and commitment to help us do so. Now the real work begins, as we will identify our capacity and resources to have an impact on national medical cannabis drugs availability. Together with our new South African research partners, we have started the process of identifying traditional populations and healers who represent thousands of years of cannabis use within cultural contexts. We believe that our partnership with cultural leaders will increase our insight into the utilities of the cannabis plant across a wide variety of health conditions. Our meetings in Cape Town represent the beginning of deep collaboration with South African communities, government, regulatory bodies, researchers, and clinical providers. We are very excited," concluded Mr. Dabney.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.